Advancements in neuroactive peptides in seizures

References

• Burbach JPH. What Are Neuropeptides? In: Merighi A, editor. Neuropeptides: methods and protocols [internet]. Totowa (NJ):Humana Press; 2011. p. 1–36.
   Google Scholar
• Burbach JPH. Neuropeptides from concept to online database www.neuropeptides.nl. Eur J Pharmacol. 2010;626(1):27–48.
   PubMed Web of Science ®Google Scholar
• Clynen E, Swijsen A, Raijmakers M, et al. Neuropeptides as targets for the development of anticonvulsant drugs. Mol Neurobiol. 2014;50(2):626–646.
   PubMed Web of Science ®Google Scholar
• Werner F-M, Covenas R. Classical neurotransmitters and neuropeptides involved in generalized epilepsy: a focus on antiepileptic drugs. Curr Med Chem. 2011;18(32):4933–4948.
   PubMed Web of Science ®Google Scholar
• Baraban SC, Tallent MK. Interneuron diversity series: interneuronal neuropeptides–endogenous regulators of neuronal excitability. Trends Neurosci. 2004;27(3):135–142.
   PubMed Web of Science ®Google Scholar
• Wasterlain CG, Mazarati AM, Naylor D, et al. Short-term plasticity of hippocampal neuropeptides and neuronal circuitry in experimental status epilepticus. Epilepsia. 2002;43(Suppl 5):20–29.
   PubMedGoogle Scholar
• Di Giannuario A, Pieretti S, Sagratella S, et al. Dexamethasone blocking effects on mu- and delta-opioid-induced seizures involves kappa-opioid activity in the rabbit. Neuropsychobiology. 2001;43(3):213–220.
   PubMed Web of Science ®Google Scholar
• Broom DC, Nitsche JF, and Pintar JE, et al. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther. 2002;303(2):723–729.
   PubMed Web of Science ®Google Scholar
• Cain DP, Corcoran ME. Intracerebral beta-endorphin, met-enkephalin and morphine: kindling of seizures and handling-induced potentiation of epileptiform effects. Life Sci. 1984;34(25):2535–2542.
   PubMed Web of Science ®Google Scholar
• Gulec G, Noyan B. Arginine vasopressin in the pathogenesis of febrile convulsion and temporal lobe epilepsy. Neuroreport. 2002;13(16):2045–2048.
   PubMed Web of Science ®Google Scholar
• Wong JC, Shapiro L, Thelin JT, et al. Nanoparticle encapsulated oxytocin increases resistance to induced seizures and restores social behavior in Scn1a-derived epilepsy. Neurobiol Dis. 2021;147:105147.
   PubMed Web of Science ®Google Scholar
• Zhang L-X, Zhou Y, Du Y, et al. Effect of CCK-8 on audiogenic epileptic seizure in P77PMC rats. Neuropeptides. 1993;25(1):73–76.
   PubMed Web of Science ®Google Scholar
• Mazarati AM, Telegdy G. Effects of somatostatin and anti-somatostatin serum on picrotoxin-kindled seizures. Neuropharmacology. 1992;31(8):793–797.
   PubMed Web of Science ®Google Scholar
• Tallent MK, and Qiu C. Somatostatin: an endogenous antiepileptic. Mol Cell Endocrinol. 2008;286(1):96–103.
   PubMed Web of Science ®Google Scholar
• Aourz N, Portelli J, Coppens J, et al. Cortistatin-14 mediates its anticonvulsant effects via sst2 and sst3 but not ghrelin receptors. CNS Neurosci Ther. 2014;20(7):662–670.
   PubMed Web of Science ®Google Scholar
• Meurs A, Clinckers R, Ebinger G, et al. Clinical potential of neuropeptide Y receptor ligands in the treatment of epilepsy. Curr Top Med Chem. 2007;7(17):1660–1674.
   PubMed Web of Science ®Google Scholar
• Chepurnova NE, Ponomarenko AA, Chepurnov SA. Peptidergic mechanisms of hyperthermia-evoked convulsions in rats in early postnatal ontogenesis. Neurosci Behav Physiol. 2002;32(5):505–511.
   PubMedGoogle Scholar
• Lee S-H, Cox CL. Excitatory actions of vasoactive intestinal peptide on mouse thalamocortical neurons are mediated by VPAC2 receptors. J Neurophysiol. 2006;96(2):858–871.
   PubMed Web of Science ®Google Scholar
• Hollrigel GS, Chen K, Baram TZ, et al. The pro-convulsant actions of corticotropin-releasing hormone in the hippocampus of infant rats. Neuroscience. 1998;84(1):71–79.
   PubMed Web of Science ®Google Scholar
• Wang XF, Ge TT, Fan J, et al. The role of substance P in epilepsy and seizure disorders. Oncotarget. 2017;8(44):78225–78233.
   PubMedGoogle Scholar
• Pereira MGAG, Becari C, and Oliveira JAC, et al. Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy. Clin Sci Lond Engl. 1979. 2010;119(11):477–482 •• Article important for understanding link between renin-angiotensin system and epilepsy.
   PubMed Web of Science ®Google Scholar
• Tanganelli S, O’Connor WT, Ferraro L, et al. Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens. Neuroscience. 1994;60(3):649–657.
   PubMed Web of Science ®Google Scholar
• Lee H-K, Zhang L, Smith MD, et al. Glycosylated neurotensin analogues exhibit sub-picomolar anticonvulsant potency in a pharmacoresistant model of epilepsy. ChemMedChem. 2009;4(3):400–405.
   PubMed Web of Science ®Google Scholar
• Ge T, Yang W, Fan J, et al. Preclinical evidence of ghrelin as a therapeutic target in epilepsy. Oncotarget. 2017;8(35):59929–59939.
   PubMedGoogle Scholar
• Lerner JT, Sankar R, Mazarati AM. Galanin and epilepsy. Cell Mol Life Sci CMLS. 2008;65(12):1864–1871.
   PubMed Web of Science ®Google Scholar
• Nie Y, Schoepp DD, Klaunig JE, et al. Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro. Brain Res. 2005;1054(1):45–54.
   PubMed Web of Science ®Google Scholar
• Kubek MJ, Garg BP. Thyrotropin-releasing hormone in the treatment of intractable epilepsy. Pediatr Neurol. 2002;26(1):9–17.
   PubMed Web of Science ®Google Scholar
• Lerner JT, Sankar R, Mazarati AM. Galanin and epilepsy. Exp Suppl 2012. 2010;102:183–194.
   PubMedGoogle Scholar
• Gao XB, and van den Pol AN. Melanin concentrating hormone depresses synaptic activity of glutamate and GABA neurons from rat lateral hypothalamus. J Physiol. 2001;533(Pt 1):237–252.
   PubMed Web of Science ®Google Scholar
• Stafstrom CE, Arnason BGW, Baram TZ, et al. Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol. 2011;26(11):1411–1421.
   PubMed Web of Science ®Google Scholar
• Burtscher J, Schwarzer C. The opioid system in temporothmanal lobe epilepsy: functional role and therapeutic potential. Front Mol Neurosci. 2017;10:245.
   PubMed Web of Science ®Google Scholar
• Kanemitsu Y, Hosoi M, and Zhu PJ, et al., Dynorphin A inhibits NMDA receptors through a pH-dependent mechanism. Mol Cell Neurosci. 24(3): 525–537. 2003
   PubMed Web of Science ®Google Scholar
• Zamanian G, Shayan M, Rahimi N, et al. Interaction of morphine tolerance with pentylenetetrazole-induced seizure threshold in mice: the role of NMDA-receptor/NO pathway. Epilepsy Behav. 2020;112:107343.
   PubMed Web of Science ®Google Scholar
• Eslami F, Rahimi N, Ostovaneh A, et al. Sumatriptan reduces severity of status epilepticus induced by lithium-pilocarpine through nitrergic transmission and 5-HT1B/D receptors in rats: a pharmacological-based evidence. Fundam Clin Pharmacol. 2021;35(1):131–140.
   PubMed Web of Science ®Google Scholar
• Schmidhammer H, Erli F, Guerrieri E, et al. Development of diphenethylamines as selective kappa opioid receptor ligands and their pharmacological activities. Mol Basel Switz. 2020;25(21):E5092.
   Google Scholar
• Bausch SB, Esteb TM, Terman GW, et al. Administered and endogenously released kappa opioids decrease pilocarpine-induced seizures and seizure-induced histopathology. J Pharmacol Exp Ther. 1998;284(3):1147–1155.
   PubMed Web of Science ®Google Scholar
• Becker A, Braun H, Schröder H, et al. Effects of enadoline on the development of pentylenetetrazol kindling, learning performance, and hippocampal morphology. Brain Res. 1999;823(1–2):191–197.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Strain EC, Abreu ME, et al. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 2001;157(2):151–162.
   PubMed Web of Science ®Google Scholar
• Mazarati A, Liu H, Wasterlain C. Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus. Neuroscience. 1999;89(1):167–173.
   PubMed Web of Science ®Google Scholar
• Yajima Y, Narita M, Takahashi-Nakano Y, et al. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse. Brain Res. 2000;862(1–2):120–126.
   PubMed Web of Science ®Google Scholar
• Chu Sin Chung P, and Kieffer BL. Delta opioid receptors in brain function and diseases. Pharmacol Ther. 2013;140(1):112–120.
   PubMed Web of Science ®Google Scholar
• Portoghese PS, Sultana M, Takemori AE. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol. 1988;146(1):185–186.
   PubMed Web of Science ®Google Scholar
• Comer SD, Hoenicke EM, Sable AI, et al. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther. 1993;267(2):888–895.
   PubMed Web of Science ®Google Scholar
• Solbrig MV, Adrian R, Wechsler SL, et al. Activators of potassium M currents have anticonvulsant actions in two rat models of encephalitis. Eur J Pharmacol. 2007;555(1):23–29.
   PubMed Web of Science ®Google Scholar
• De Sarro GB, Marra R, Spagnolo C, et al. Delta opioid receptors mediate seizures produced by intrahippocampal injection of ala-deltorphin in rats. Funct Neurol. 1992;7(3):235–238.
   PubMedGoogle Scholar
• Lasoń W, Przewłocka B, Coenen A, et al. Effects of mu and delta opioid receptor agonists and antagonists on absence epilepsy in WAG/Rij rats. Neuropharmacology. 1994;33(2):161–166.
   PubMed Web of Science ®Google Scholar
• Jackson HC, and Nutt DJ. Differential effects of selective mu-, kappa- and delta-opioid antagonists on electroshock seizure threshold in mice. Psychopharmacology (Berl). 1991;103(3):380–383.
   PubMed Web of Science ®Google Scholar
• Margolis EB, Fujita W, Devi LA, et al. Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor. Neuropharmacology. 2017;123:420–432.
   PubMed Web of Science ®Google Scholar
• Broom DC, Guo L, Coop A, et al. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice. J Pharmacol Exp Ther. 2000;294(3):1195–1200.
   PubMed Web of Science ®Google Scholar
• Berna MJ, Tapia JA, Sancho V, et al. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol. 2007;7(6):583–592.
   PubMed Web of Science ®Google Scholar
• Miller LJ, Gao F. Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther. 2008;119(1):83–95.
   PubMed Web of Science ®Google Scholar
• Wyeth MS, Zhang N, Mody I, et al. Selective reduction of cholecystokinin-positive basket cell innervation in a model of temporal lobe epilepsy. J Neurosci Off J Soc Neurosci. 2010;30(26):8993–9006.
   PubMed Web of Science ®Google Scholar
• Schwarzer C, Williamson JM, Lothman EW, et al. Somatostatin, neuropeptide Y, neurokinin B and cholecystokinin immunoreactivity in two chronic models of temporal lobe epilepsy. Neuroscience. 1995;69(3):831–845.
   PubMed Web of Science ®Google Scholar
• Ferraro G, Sardo P. Cholecystokinin-8 sulfate modulates the anticonvulsant efficacy of vigabatrin in an experimental model of partial complex epilepsy in the rat. Epilepsia. 2009;50(4):721–730.
   PubMed Web of Science ®Google Scholar
• Deng P-Y, Lei S. Bidirectional modulation of GABAergic transmission by cholecystokinin in hippocampal dentate gyrus granule cells of juvenile rats. J Physiol. 2006;572(Pt 2):425–442.
   PubMed Web of Science ®Google Scholar
• Zhang LX, Wu M, Han JS. Suppression of audiogenic epileptic seizures by intracerebral injection of a CCK gene vector. Neuroreport. 1992;3(8):700–702.
   PubMed Web of Science ®Google Scholar
• Dunlop J. CCK receptor antagonists. Gen Pharmacol. 1998;31(4):519–524.
   PubMedGoogle Scholar
• Sparapani S, Millet-Boureima C, Oliver J, et al. The biology of vasopressin. Biomedicines. 2021;9(1):89.
   PubMed Web of Science ®Google Scholar
• Javadian N, Rahimi N, Javadi-Paydar M, et al. The modulatory effect of nitric oxide in pro- and anti-convulsive effects of vasopressin in PTZ-induced seizures threshold in mice. Epilepsy Res. 2016;126:134–140.
   PubMed Web of Science ®Google Scholar
• Greenwood RS, Fan Z, Meeker R. Persistent elevation of corticotrophin releasing factor and vasopressin but not oxytocin mRNA in the rat after kindled seizures. Neurosci Lett. 1997;224(1):66–70.
   PubMed Web of Science ®Google Scholar
• Greenwood RS, Meeker RB, Abdou A, et al. Kindled seizures induce a long-term increase in vasopressin mRNA. Brain Res Mol Brain Res. 1994;24(1–4):20–26.
   PubMedGoogle Scholar
• Ślusarz MJ. Vasopressin V1a and V1b receptor modulators: a patent review (2012 – 2014). Expert Opin Ther Pat. 2015;25(6):711–722.
   PubMed Web of Science ®Google Scholar
• Lin Y-T, Hsu K-S. Oxytocin receptor signaling in the hippocampus: role in regulating neuronal excitability, network oscillatory activity, synaptic plasticity and social memory. Prog Neurobiol. 2018;171:1–14.
   PubMed Web of Science ®Google Scholar
• Chatterjee O, Patil K, Sahu A, et al. An overview of the oxytocin-oxytocin receptor signaling network. J Cell Commun Signal. 2016;10(4):355–360.
   PubMed Web of Science ®Google Scholar
• Erbas O, Yılmaz M, Korkmaz HA, et al. Oxytocin inhibits pentylentetrazol-induced seizures in the rat. Peptides. 2013;40:141–144.
   PubMed Web of Science ®Google Scholar
• Erfanparast A, Tamaddonfard E, Henareh-Chareh F. Intra-hippocampal microinjection of oxytocin produced antiepileptic effect on the pentylenetetrazol-induced epilepsy in rats. Pharmacol Rep PR. 2017;69(4):757–763.
   PubMed Web of Science ®Google Scholar
• Rahimian R, Khoshneviszadeh M, Bahremand T, et al. Oxytocinergic system mediates the proconvulsant effects of sildenafil: the role of calcineurin. Horm Behav. 2020;122:104753.
   PubMed Web of Science ®Google Scholar
• Bichet D, Bouvier M, Chini B, et al. Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS guide to pharmacology database. IUPHARBPS Guide Pharmacol CITE. 2019;2019(4).
   Google Scholar
• Home - ClinicalTrials.gov [Internet]. cited 2021 Jul 7]. Available from: https://clinicaltrials.gov/ct2/home
   Google Scholar
• Colmers WF, El Bahh B. Neuropeptide Y and epilepsy. Epilepsy Curr. 2003;3(2):53–58.
   PubMedGoogle Scholar
• Baraban SC. Neuropeptide Y and epilepsy: recent progress, prospects and controversies. Neuropeptides. 2004;38(4):261–265.
   PubMed Web of Science ®Google Scholar
• Mittapalli GK, Roberts E. Ligands of the neuropeptide Y Y2 receptor. Bioorg Med Chem Lett. 2014;24(2):430–441.
   PubMed Web of Science ®Google Scholar
• Vezzani A, Moneta D, Mulé F, et al. Plastic changes in neuropeptide Y receptor subtypes in experimental models of limbic seizures. Epilepsia. 2000;41(Suppl 6):S115–121.
   PubMedGoogle Scholar
• Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003;20(3):255–264.
   PubMed Web of Science ®Google Scholar
• Hannon JP, Nunn C, and Stolz B, et al., Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci. 18(1–2): 15–27. 2002
   PubMed Web of Science ®Google Scholar
• Aourz N, De Bundel D, Stragier B, et al. Rat hippocampal somatostatin sst3 and sst4 receptors mediate anticonvulsive effects in vivo: indications of functional interactions with sst2 receptors. Neuropharmacology. 2011;61(8):1327–1333.
   PubMed Web of Science ®Google Scholar
• Moneta D, Richichi C, Aliprandi M, et al. Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur J Neurosci. 2002;16(5):843–849.
   PubMed Web of Science ®Google Scholar
• Ibáñez-Costa A, Luque RM, Castaño JP. Cortistatin: a new link between the growth hormone/prolactin axis, stress, and metabolism. Growth Horm IGF Res. 2017;33:23–27.
   PubMed Web of Science ®Google Scholar
• Hill JL, Jimenez DV, Mai Y, et al. Cortistatin-expressing interneurons require TrkB signaling to suppress neural hyper-excitability. Brain Struct Funct. 2019;224(1):471–483.
   PubMed Web of Science ®Google Scholar
• Maynard KR, Kardian A, Hill JL, et al. TrkB signaling influences gene expression in cortistatin-expressing interneurons. eNeuro. 2020;7(1):ENEURO.0310–19.2019.
   PubMed Web of Science ®Google Scholar
• Braun H, Schulz S, Becker A, et al. Protective effects of cortistatin (CST-14) against kainate-induced neurotoxicity in rat brain. Brain Res. 1998;803(1):54–60.
   PubMed Web of Science ®Google Scholar
• Smolders IJ, Stragier B, Meurs A, et al. The effects of cortistatin-14 on seizure severity and hippocampal neurotransmitter levels in the acute pilocarpine rat model for limbic epilepsy. Acta Physiol. 2007;191(s660):6.
   Google Scholar
• Denes V, Geck P, Mester A, et al. Pituitary adenylate cyclase-activating polypeptide: 30 years in research spotlight and 600 million years in service. J Clin Med. 2019;8(9):1488.
   Web of Science ®Google Scholar
• Kaneko Y, Tuazon JP, Ji X, et al. Pituitary adenylate cyclase activating polypeptide elicits neuroprotection against acute ischemic neuronal cell death associated with NMDA receptors. Cell Physiol Biochem. 2018;51(4):1982–1995.
   PubMedGoogle Scholar
• Nomura M, Ueta Y, Hannibal J, et al. Induction of pituitary adenylate cyclase-activating polypeptide mRNA in the medial parvocellular part of the paraventricular nucleus of rats following kainic-acid-induced seizure. Neuroendocrinology. 2000;71(5):318–326.
   PubMed Web of Science ®Google Scholar
• Gupte RP, Kadunganattil S, Shepherd AJ, et al. Convergent phosphomodulation of the major neuronal dendritic potassium channel Kv4.2 by pituitary adenylate cyclase-activating polypeptide. Neuropharmacology. 2016;101:291–308.
   PubMed Web of Science ®Google Scholar
• Sun -Q-Q, Prince DA, Huguenard JR. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide activate hyperpolarization-activated cationic current and depolarize thalamocortical neurons in vitro. J Neurosci. 2003;23(7):2751–2758.
   PubMed Web of Science ®Google Scholar
• Figiel M, and Engele J. Pituitary adenylate cyclase-activating polypeptide (pacap), a neuron-derived peptide regulating glial glutamate transport and metabolism. J Neurosci. 2000;20(10):3596–3605.
   PubMed Web of Science ®Google Scholar
• Iwasaki M, Akiba Y, Kaunitz JD. Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. F1000Res. 2019;8:F1000. Faculty Rev-1629.
   PubMedGoogle Scholar
• Goff KM, Goldberg EM. Vasoactive intestinal peptide-expressing interneurons are impaired in a mouse model of Dravet syndrome. eLife. 2019;8:e46846.
   PubMed Web of Science ®Google Scholar
• Kilinc E, Gunes H. Modulatory effects of neuropeptides on pentylenetetrazol-induced epileptic seizures and neuroinflammation in rats. Rev Assoc Medica Bras 1992 .2019;65(9):1188–1192.
   PubMed Web of Science ®Google Scholar
• Funabashi T, Hiruma H, Arita J, et al. Intraventricular injection of vasoactive intestinal polypeptide facilitates the development of amygdaloid kindling. Brain Res. 1991;541(1):110–114.
   PubMed Web of Science ®Google Scholar
• Cǎlin A, Stancu M, and Zagrean A-M, et al. Chemogenetic recruitment of specific interneurons suppresses seizure activity. Front Cell Neurosci. 2018;12:293.
   PubMed Web of Science ®Google Scholar
• Ko FJ, Chiang CH, Liu WJ, et al. Somatostatin, substance P, prolactin and vasoactive intestinal peptide levels in serum and cerebrospinal fluid of children with seizure disorders. Gaoxiong Yi Xue Ke Xue Za Zhi. 1991;7(8):391–397.
   PubMedGoogle Scholar
• Marksteiner J, Sperk G, Maas D. Differential increases in brain levels of neuropeptide Y and vasoactive intestinal polypeptide after kainic acid-induced seizures in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1989;339(1):173–177.
   PubMed Web of Science ®Google Scholar
• Romualdi P, Lesa G, Donatini A, et al. Alterations in vasoactive intestinal polypeptide-related peptides after pentylenetetrazole-induced seizures in rat brain. Eur J Pharmacol. 1992;229(2):149–153.
   PubMed Web of Science ®Google Scholar
• Zieglgänsberger W. Substance P and pain chronicity. Cell Tissue Res. 2019;375(1):227–241.
   PubMed Web of Science ®Google Scholar
• Kalinichev M, Bradford A, Bison S, et al. Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat. Epilepsia. 2010;51(8):1543–1551.
   PubMed Web of Science ®Google Scholar
• McLean S, Ganong A, Seymour PA, et al. Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor. J Pharmacol Exp Ther. 1996;277(2):900–908.
   PubMed Web of Science ®Google Scholar
• Zachrisson O, Lindefors N, Brené S. A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity. Brain Res Mol Brain Res. 1998;60(2):291–295.
   PubMedGoogle Scholar
• Marksteiner J, Wahler R, Bellmann R, et al. Limbic seizures cause pronounced changes in the expression of neurokinin B in the hippocampus of the rat. Neuroscience. 1992;49(2):383–395.
   PubMed Web of Science ®Google Scholar
• Marksteiner J, Lassmann H, Saria A, et al. Neuropeptide levels after pentylenetetrazol kindling in the rat. Eur J Neurosci. 1990;2(1):98–103.
   PubMed Web of Science ®Google Scholar
• Röder C, Bellmann R, McCarson KE, et al. Kainic acid induced seizures cause a marked increase in the expression of neurokinin-3 receptor mRNA in the rat cerebellum. Neurosci Lett. 1994;181(1–2):158–160.
   PubMed Web of Science ®Google Scholar
• Stenfors C, Srinivasan GR, Theodorsson E, et al. Electroconvulsive stimuli and brain peptides: effect of modification of seizure duration on neuropeptide Y, neurokinin A, substance P and neurotensin. Brain Res. 1992;596(1–2):251–258.
   PubMed Web of Science ®Google Scholar
• Phan J The role of neurokinin-B in seizure and epilepsy. urc_student [Internet]. [0:00 cited 2021 Aug 18]; Available from: https://scholar.oxy.edu/handle/20.500.12711/450
   Google Scholar
• Muñoz M, and Coveñas R. Neurokinin receptor antagonism: a patent review (2014-present). Expert Opin Ther Pat. 2020;30(7):527–539.
   PubMed Web of Science ®Google Scholar
• Inda C, Armando NG, Dos S CPA, et al. Endocrinology and the brain: corticotropin-releasing hormone signaling. Endocr Connect. 2017;6(6):R99–120.
   PubMed Web of Science ®Google Scholar
• Gunn BG, Baram TZ. Stress and seizures: space, time and hippocampal circuits. Trends Neurosci. 2017;40(11):667–679.
   PubMed Web of Science ®Google Scholar
• Zoumakis E, Chrousos GP. Corticotropin-releasing hormone receptor antagonists: an update. Endocr Dev. 2010;17:36–43.
   PubMedGoogle Scholar
• O’Toole KK, Hooper A, Wakefield S, et al. Seizure-induced disinhibition of the HPA axis increases seizure susceptibility. Epilepsy Res. 2014;108(1):29–43.
   PubMed Web of Science ®Google Scholar
• Yuhas Y, Weizman A, Chrousos GP, et al. Involvement of the neuropeptide corticotropin-releasing hormone in an animal model of shigella-related seizures. J Neuroimmunol. 2004;153(1–2):36–39.
   PubMed Web of Science ®Google Scholar
• Lu H, Cassis LA, Kooi CWV, et al. Structure and functions of angiotensinogen. Hypertens Res Off J Jpn Soc Hypertens. 2016;39(7):492–500
   PubMed Web of Science ®Google Scholar
• Uijl E, Ren L, and Danser AHJ. Angiotensin generation in the brain: a re-evaluation. Clin Sci Lond Engl 1979. 2018;132(8):839–850. .
   Google Scholar
• Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: an update. Saudi J Biol Sci. 2020;27(3):905–912.
   PubMed Web of Science ®Google Scholar
• Becari C, Pereira GL, Oliveira JAC, et al. Epilepsy seizures in spontaneously hypertensive rats after acoustic stimulation: role of renin-angiotensin system. Front Neurosci. 2020;14:588477.
   PubMed Web of Science ®Google Scholar
• Georgiev VP, Lazarova MB, Petkov VD, et al. Interactions between angiotensin II, GABA and diazepam in convulsive seizures. Neuropeptides. 1986;7(4):329–336.
   PubMed Web of Science ®Google Scholar
• Gomes KP, Braga PPP, de Lima CQ, et al. Antiepileptic effects of long-term intracerebroventricular infusion of angiotensin-(1-7) in an animal model of temporal lobe epilepsy. Clin Sci Lond Engl 1979. 2020;134(17): 2263–2277
   PubMed Web of Science ®Google Scholar
• Nozaki T, Ura H, Takumi I, et al. The angiotensin II type I receptor antagonist losartan retards amygdala kindling-induced epileptogenesis. Brain Res. 2018;1694:121–128.
   PubMed Web of Science ®Google Scholar
• Łukawski K, Raszewski G, Czuczwar SJ. Effect of aliskiren on the anticonvulsant activity of antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice. Epilepsy Res. 2020;167:106435.
   PubMed Web of Science ®Google Scholar
• Sarro GD, Paola EDD, and Gratteri S, et al., Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacol Res. 65(3): 285–296. 2012
   PubMed Web of Science ®Google Scholar
• Łukawski K, Janowska A, Jakubus T, et al. Interactions between angiotensin AT1 receptor antagonists and second-generation antiepileptic drugs in the test of maximal electroshock. Fundam Clin Pharmacol. 2014;28(3):277–283.
   PubMed Web of Science ®Google Scholar
• Tan J, Wang JM, Leenen FHH. Inhibition of brain angiotensin-converting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats. Am J Hypertens. 2005;18(2):158–164.
   PubMed Web of Science ®Google Scholar
• Tschumi CW, Beckstead MJ. Diverse actions of the modulatory peptide neurotensin on central synaptic transmission. Eur J Neurosci. 2019;49(6):784–793.
   PubMed Web of Science ®Google Scholar
• Sperk G, Wieser R, Widmann R, et al. Kainic acid induced seizures: changes in somatostatin, substance P and neurotensin. Neuroscience. 1986;17(4):1117–1126.
   PubMed Web of Science ®Google Scholar
• Kyriatzis G, Bernard A, Bôle A, et al. Neurotensin receptor 2 is induced in astrocytes and brain endothelial cells in relation to neuroinflammation following pilocarpine-induced seizures in rats. Glia. 2021 Jul 26;69(11):2618–2643. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Shandra OA, Hodlevskyĭ LS, Vastíanov RS, et al. Effect of intracerebral injections of somatostatin and neurotensin on motor functions in seizure. Fiziol Zh. 1993;39(5–6):76–82.
   PubMedGoogle Scholar
• Hashiguchi S, Masuda T, Fujimoto H, et al. Involvements of neuropeptides in pentylenetetrazol-induced convulsion in rats and effects of TRH and ceruletide on the convulsion. No To Shinkei. 1990;42(1):73–78.
   PubMedGoogle Scholar
• Kojima M, and Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85(2):495–522.
   PubMed Web of Science ®Google Scholar
• Giordano C, Marchiò M, Timofeeva E, et al. Neuroactive peptides as putative mediators of antiepileptic ketogenic diets. Front Neurol. 2014;5(63):1–14.
   PubMedGoogle Scholar
• Lucchi C, Curia G, Vinet J, et al. Protective but not anticonvulsant effects of ghrelin and JMV-1843 in the pilocarpine model of status epilepticus. PloS One. 2013;8(8):e72716.
   PubMed Web of Science ®Google Scholar
• Giordano C, Costa AM, Lucchi C, et al. Progressive seizure aggravation in the repeated 6-hz corneal stimulation model is accompanied by marked increase in hippocampal p-erk1/2 immunoreactivity in neurons. Front Cell Neurosci. 2016;10(281):1–12.
   PubMedGoogle Scholar
• Lucchi C, Costa AM, Giordano C, et al. Involvement of PPARγ in the anticonvulsant activity of ep-80317, a ghrelin receptor antagonist. Front Pharmacol. 2017;8(676):1–13.
   PubMedGoogle Scholar
• Marchiò M, Roli L, Giordano C, et al. High plasma levels of ghrelin and des-acyl ghrelin in responders to antiepileptic drugs. Neurology. 2018;91(1):e62–6.
   PubMed Web of Science ®Google Scholar
• Marchiò M, Roli L, Giordano C, et al. Decreased ghrelin and des-acyl ghrelin plasma levels in patients affected by pharmacoresistant epilepsy and maintained on the ketogenic diet. Clin Nutr Edinb Scotl. 2019;38(2):954–957.
   PubMed Web of Science ®Google Scholar
• Marchiò M, Roli L, Lucchi C, et al. ghrelin plasma levels after 1 year of ketogenic diet in children with refractory epilepsy. Front Nutr. 2019;6(112):1–6.
   PubMedGoogle Scholar
• Buckinx A, Pierre A, Van Den Herrewegen Y, et al. Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy. Eur J Neurol. 2021;28(9):3100–3112.
   PubMed Web of Science ®Google Scholar
• Buckinx A, Van Den Herrewegen Y, Pierre A, et al. Differential effects of a full and biased ghrelin receptor agonist in a mouse kindling model. Int J Mol Sci. 2019;20(10):E2480.
   PubMed Web of Science ®Google Scholar
• Šípková J, Kramáriková I, and Hynie S, et al. The galanin and galanin receptor subtypes, its regulatory role in the biological and pathological functions. Physiol Res. 2017;66(5):729–740.
   PubMed Web of Science ®Google Scholar
• Tiong SYX, Polgár E, van Kralingen JC, et al. Galanin-immunoreactivity identifies a distinct population of inhibitory interneurons in laminae I-III of the rat spinal cord. Mol Pain. 2011;7:36.
   PubMed Web of Science ®Google Scholar
• Christiansen SH, Woldbye DPD. Regulation of the galanin system by repeated electroconvulsive seizures in mice. J Neurosci Res. 2010;88(16):3635–3643.
   PubMed Web of Science ®Google Scholar
• Mazarati AM, Liu H, Soomets U, et al. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci Off J Soc Neurosci. 1998;18(23):10070–10077.
   PubMed Web of Science ®Google Scholar
• Mazarati A, Lu X. Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors. Neuropeptides. 2005;39(3):277–280.
   PubMed Web of Science ®Google Scholar
• Drexel M, Locker F, Kofler B, et al. Effects of galanin receptor 2 and receptor 3 knockout in mouse models of acute seizures. Epilepsia. 2018;59(11):e166–71.
   PubMed Web of Science ®Google Scholar
• Saar K, Mazarati AM, Mahlapuu R, et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A. 2002;99(10):7136–7141.
   PubMed Web of Science ®Google Scholar
• Engel S, Gershengorn MC. Thyrotropin-releasing hormone and its receptors–a hypothesis for binding and receptor activation. Pharmacol Ther. 2007;113(2):410–419.
   PubMed Web of Science ®Google Scholar
• Manaker S, Winokur A, Rostene WH, et al. Autoradiographic localization of thyrotropin-releasing hormone receptors in the rat central nervous system. J Neurosci Off J Soc Neurosci. 1985;5(1):167–174.
   PubMed Web of Science ®Google Scholar
• Asai H, Kinoshita K, Yamamura M, et al. Diversity of thyrotropin-releasing hormone receptors in the pituitary and discrete brain regions of rats. Jpn J Pharmacol. 1999;79(3):313–317.
   PubMedGoogle Scholar
• Jaworska-Feil L, Turchan J, Przewłocka B, et al. Effects of pilocarpine- and kainate-induced seizures on thyrotropin-releasing hormone biosynthesis and receptors in the rat brain. J Neural Transm Vienna Austria 1996. 1999;106(5–6):395–407.
   PubMed Web of Science ®Google Scholar
• Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39–57.
   PubMed Web of Science ®Google Scholar
• Renming X, Ishihara K, Sasa M, et al. Antiepileptic effects of CNK-602A, a novel thyrotropin-releasing hormone analog, on absence-like and tonic seizures of spontaneously epileptic rats. Eur J Pharmacol. 1992;223(2–3):185–192.
   PubMed Web of Science ®Google Scholar
• Yatsugi S, Yamamoto M. Anticonvulsive properties of YM-14673, a new TRH analogue, in amygdaloid-kindled rats. Pharmacol Biochem Behav. 1991;38(3):669–672.
   PubMed Web of Science ®Google Scholar
• Jaworska-Feil L, Kajta M, Budziszewska B, et al. Protective effects of TRH and its stable analogue, RGH-2202, on kainate-induced seizures and neurotoxicity in rodents. Epilepsy Res. 2001;43(1):67–73.
   PubMed Web of Science ®Google Scholar
• Mori N, Fukatsu T. Anticonvulsant effect of DN-1417, a derivative of thyrotropin-releasing hormone, and liposome-entrapped DN-1417, on amygdaloid-kindled rats. Epilepsia. 1992;33(6):994–1000.
   PubMed Web of Science ®Google Scholar
• Sakai S, Baba H, Sato M, et al. Effect of DN-1417 on photosensitivity and cortically kindled seizure in Senegalese baboons, Papio papio. Epilepsia. 1991;32(1):16–21.
   PubMed Web of Science ®Google Scholar
• Ogawa T, Moriwake T, Morimoto K, et al. The effect of a novel TRH analog (DN-1417) on postictal seizure inhibition in amygdaloid kindled cats. No To Shinkei. 1984;36(10):951–955.
   PubMedGoogle Scholar
• Jancsik V, Bene R, and Sótonyi P, et al. Sub-cellular organization of the melanin-concentrating hormone neurons in the hypothalamus. Peptides. 2018;99:56–60.
   PubMed Web of Science ®Google Scholar
• Diniz GB, Bittencourt JC. The Melanin-Concentrating Hormone (MCH) system: a tale of two peptides. Front Neurosci. 2019;13:1280.
   PubMed Web of Science ®Google Scholar
• Knigge KM, Wagner JE. Melanin-concentrating hormone (MCH) involvement in pentylenetetrazole (PTZ)-induced seizure in rat and guinea pig. Peptides. 1997;18(7):1095–1097.
   PubMed Web of Science ®Google Scholar
• Parks GS, Okumura SM, Gohil K, et al. Mice lacking melanin concentrating hormone 1 receptor are resistant to seizures. Neurosci Lett. 2010;484(2):104–107.
   PubMed Web of Science ®Google Scholar
• Boutin JA, Suply T, Audinot V, et al. Melanin-concentrating hormone and its receptors: state of the art. Can J Physiol Pharmacol. 2002;80(5):388–395.
   PubMed Web of Science ®Google Scholar
• Nagasaki H, Chung S, Dooley CT, et al. The pharmacological properties of a novel MCH1 receptor antagonist isolated from combinatorial libraries. Eur J Pharmacol. 2009;602(2–3):194–202.
   PubMed Web of Science ®Google Scholar
• Cippitelli A, Karlsson C, Shaw JL, et al. Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. Psychopharmacology (Berl). 2010;211(4):367–375.
   PubMed Web of Science ®Google Scholar
• Ghaddhab C, Vuissoz J-M, Deladoëy J. From bioinactive ACTH to ACTH antagonist: the clinical perspective. Front Endocrinol. 2017;8:17.
   PubMed Web of Science ®Google Scholar
• D’Alonzo R, Rigante D, Mencaroni E, et al. West syndrome: a review and guide for paediatricians. Clin Drug Investig. 2018;38(2):113–124.
   PubMed Web of Science ®Google Scholar
• Trivisano M, Lucchi C, Rustichelli C, et al. Reduced steroidogenesis in patients with PCDH19-female limited epilepsy. Epilepsia. 2017;58(6):e91–5.
   PubMed Web of Science ®Google Scholar
• Baba S, Okanishi T, Homma Y, et al. Efficacy of long-term adrenocorticotropic hormone therapy for West syndrome: a retrospective multicenter case series. Epilepsia Open. 2021;6(2):402–412.
   PubMedGoogle Scholar
• Wanigasinghe J, Arambepola C, Ranganathan SS, et al. Epilepsy outcome at four years in a randomized clinical trial comparing oral prednisolone and intramuscular ACTH in West syndrome. Pediatr Neurol. 2021;119:22–26.
   PubMed Web of Science ®Google Scholar
• He S, Ye Z, Dobbelaar PH, et al. Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist. Bioorg Med Chem Lett. 2010;20(7):2106–2110.
   PubMed Web of Science ®Google Scholar
• Hong Q, Bakshi RK, Palucki BL, et al. Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Bioorg Med Chem Lett. 2011;21(8):2330–2334.
   PubMed Web of Science ®Google Scholar